<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009711</url>
  </required_header>
  <id_info>
    <org_study_id>1097.00</org_study_id>
    <secondary_id>FHCRC-1097.00</secondary_id>
    <secondary_id>NCI-G00-1911</secondary_id>
    <secondary_id>CDR0000065808</secondary_id>
    <nct_id>NCT00009711</nct_id>
  </id_info>
  <brief_title>Study of Lung Function in Children Who Have Undergone Bone Marrow Transplantation</brief_title>
  <official_title>The Impact of Pediatric Marrow Transplantation on Late Pulmonary Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Assessing the long-term effects of bone marrow transplant on lung function in&#xD;
      patients may improve the ability to plan treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial studies lung function in pediatric patients who have undergone&#xD;
      bone marrow transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the delayed effects of bone marrow transplantation preparative regimens on&#xD;
           pulmonary function in children surviving at least 5 years after transplantation for&#xD;
           hematologic malignancy.&#xD;
&#xD;
        -  Determine the relationship between pulmonary function and growth rates in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the effect of growth hormone treatment on pulmonary function in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the relationship between pulmonary function and age at time of transplantation&#xD;
           in these patients.&#xD;
&#xD;
        -  Determine the incidence and severity of restrictive pulmonary disease, and whether these&#xD;
           factors vary with increasing time after transplantation in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo respiratory history, signs and symptoms assessment, pulmonary&#xD;
      function tests (PFT) including spirometry, lung volumes, and diffusion, oxygen saturation by&#xD;
      pulse oximetry, and height measurement.&#xD;
&#xD;
      Patients are assessed at 5-10 years, 10-15 years, and over 15 years after bone marrow&#xD;
      transplantation. Patients with abnormal PFTs are assessed at more frequent intervals as&#xD;
      clinically indicated.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 280 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Long-term Effects Secondary to Cancer Therapy in Children</condition>
  <condition>Pulmonary Complications</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Patients who have undergone bone marrow transplantation for hematologic malignancy at&#xD;
             least 5 years ago&#xD;
&#xD;
               -  Disease-free survivors at least 6 years of age AND&#xD;
&#xD;
               -  Under 18 years of age at time of transplantation&#xD;
&#xD;
          -  Received prior allogeneic, unrelated donor, syngeneic, or autologous bone marrow&#xD;
             transplantation&#xD;
&#xD;
          -  Able to perform pulmonary function tests&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Any prior preparative regimen allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean E. Sanders, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 29, 2013</last_update_submitted>
  <last_update_submitted_qc>April 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <keyword>long-term effects secondary to cancer therapy in children</keyword>
  <keyword>pulmonary complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

